CA2266378C - Use of sibutramine analogues to lower lipid levels - Google Patents

Use of sibutramine analogues to lower lipid levels Download PDF

Info

Publication number
CA2266378C
CA2266378C CA002266378A CA2266378A CA2266378C CA 2266378 C CA2266378 C CA 2266378C CA 002266378 A CA002266378 A CA 002266378A CA 2266378 A CA2266378 A CA 2266378A CA 2266378 C CA2266378 C CA 2266378C
Authority
CA
Canada
Prior art keywords
compound
formula
pharmaceutically acceptable
chlorophenyl
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002266378A
Other languages
English (en)
French (fr)
Other versions
CA2266378A1 (en
Inventor
Peter Finian Kelly
Stephen Paul Jones
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott GmbH and Co KG
Original Assignee
Abbott GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott GmbH and Co KG filed Critical Abbott GmbH and Co KG
Publication of CA2266378A1 publication Critical patent/CA2266378A1/en
Application granted granted Critical
Publication of CA2266378C publication Critical patent/CA2266378C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Fats And Perfumes (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Analogue/Digital Conversion (AREA)
CA002266378A 1996-09-25 1997-09-15 Use of sibutramine analogues to lower lipid levels Expired - Fee Related CA2266378C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9619961.7 1996-09-25
GBGB9619961.7A GB9619961D0 (en) 1996-09-25 1996-09-25 Medical treatment
PCT/EP1997/005040 WO1998013034A1 (en) 1996-09-25 1997-09-15 Use of sibutramine analogues to lower lipid levels

Publications (2)

Publication Number Publication Date
CA2266378A1 CA2266378A1 (en) 1998-04-02
CA2266378C true CA2266378C (en) 2007-02-13

Family

ID=10800447

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002266378A Expired - Fee Related CA2266378C (en) 1996-09-25 1997-09-15 Use of sibutramine analogues to lower lipid levels

Country Status (26)

Country Link
US (1) US6187820B1 (zh)
EP (1) EP0973511B1 (zh)
JP (1) JP4143126B2 (zh)
KR (1) KR100573333B1 (zh)
CN (1) CN1173696C (zh)
AT (1) ATE239459T1 (zh)
AU (1) AU724645B2 (zh)
BG (1) BG64472B1 (zh)
BR (1) BR9711411A (zh)
CA (1) CA2266378C (zh)
CZ (1) CZ291879B6 (zh)
DE (1) DE69721833T2 (zh)
DK (1) DK0973511T3 (zh)
ES (1) ES2199354T3 (zh)
GB (1) GB9619961D0 (zh)
HU (1) HU224711B1 (zh)
IL (1) IL128820A (zh)
NO (1) NO991424D0 (zh)
NZ (1) NZ334550A (zh)
PL (1) PL190017B1 (zh)
PT (1) PT973511E (zh)
RU (1) RU2197959C2 (zh)
SK (1) SK284282B6 (zh)
TR (1) TR199900648T2 (zh)
UA (1) UA63916C2 (zh)
WO (1) WO1998013034A1 (zh)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6331571B1 (en) * 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
AU2007200334B8 (en) * 1998-08-24 2010-10-21 Sepracor, Inc. Methods of using and compositions comprising dopamine reuptake inhibitors
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6046242A (en) * 1998-11-27 2000-04-04 Basf Aktiengesellschaft Use of aryl-substituted cyclobutylalkylamines for treating urinary incontinence
US6323242B1 (en) 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
US6696495B2 (en) 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
WO2000056308A1 (en) * 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Prevention of cardiovascular disease
US6552087B1 (en) 1999-03-19 2003-04-22 Abbott Gmbh & Co. Kg Therapeutic agent comprising (+)-sibutramine
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
FR2814678B1 (fr) * 2000-10-04 2002-12-20 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite
WO2002083631A1 (en) 2001-04-13 2002-10-24 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
BR0315084A (pt) * 2002-10-05 2005-08-16 Hanmi Pharm Ind Co Ltd Composição farmacêutica compreendendo hemiidrato cristalino de metanossulfonato de sibutramina
WO2004096202A1 (en) * 2003-04-28 2004-11-11 Cipla Limited Pharmaceutical formulation comprising anti-obesity agent and acidulant
US20050131074A1 (en) * 2003-08-04 2005-06-16 Beckman Kristen M. Methods for treating metabolic syndrome
US20050032908A1 (en) * 2003-08-04 2005-02-10 Beckman Kristen M. Methods for treating metabolic syndrome
KR100618176B1 (ko) 2004-12-02 2006-09-01 휴먼팜 주식회사 시부트라민 주석산염, 이의 제조 방법 및 이를 포함하는약학적 조성물
JP2008526836A (ja) * 2005-01-06 2008-07-24 シージェー チェイルジェダン コーポレーション シブトラミンの無機酸塩
KR20060080817A (ko) 2005-01-06 2006-07-11 씨제이 주식회사 시부트라민의 디카복실산염
KR20060080818A (ko) * 2005-01-06 2006-07-11 씨제이 주식회사 시부트라민의 술폰산염
KR20060093564A (ko) * 2005-02-22 2006-08-25 종근당바이오 주식회사 무수 시부트라민 말산염 및 이의 제조 방법
KR100627687B1 (ko) * 2005-04-20 2006-09-25 주식회사 씨티씨바이오 시부트라민 유리염기 함유 조성물 및 이의 제조방법
KR100814384B1 (ko) * 2006-02-10 2008-03-18 대화제약 주식회사 시부트라민 염을 함유하는 약학 조성물 및 이의 제조방법
US8604244B2 (en) 2010-07-02 2013-12-10 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
JP2010503709A (ja) 2006-09-15 2010-02-04 レビバ ファーマシューティカルズ，インコーポレーテッド シクロアルキルメチルアミンの合成、使用方法および組成物
AU2007322477A1 (en) * 2006-11-22 2008-05-29 Sk Chemicals Co., Ltd. Inclusion complex of sibutramine and beta-cyclodextrin
WO2010082216A2 (en) * 2008-12-08 2010-07-22 Matrix Laboratories Ltd Novel salts of sibutramine and their crystal forms
KR20140110014A (ko) 2011-12-30 2014-09-16 레비바 파마슈티칼스, 아이엔씨. 페닐시클로알킬메틸아민 유도체의 조성물, 합성, 및 사용 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52768B1 (en) * 1981-04-06 1988-02-17 Boots Co Ltd 1-arylcyclobutylalkylamine compounds useful as therapeutic agents
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
JP2675573B2 (ja) * 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤
IE61928B1 (en) * 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
US5459164A (en) * 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment

Also Published As

Publication number Publication date
CZ291879B6 (cs) 2003-06-18
DE69721833T2 (de) 2003-12-24
DK0973511T3 (da) 2003-08-25
KR100573333B1 (ko) 2006-04-24
UA63916C2 (uk) 2004-02-16
PL332367A1 (en) 1999-09-13
DE69721833D1 (de) 2003-06-12
RU2197959C2 (ru) 2003-02-10
CN1173696C (zh) 2004-11-03
AU724645B2 (en) 2000-09-28
SK284282B6 (sk) 2004-12-01
US6187820B1 (en) 2001-02-13
CZ93299A3 (cs) 2000-07-12
PL190017B1 (pl) 2005-10-31
BG103249A (en) 1999-09-30
IL128820A0 (en) 2000-01-31
ATE239459T1 (de) 2003-05-15
SK32099A3 (en) 1999-12-10
WO1998013034A1 (en) 1998-04-02
NO991424L (no) 1999-03-24
NO991424D0 (no) 1999-03-24
IL128820A (en) 2001-10-31
JP4143126B2 (ja) 2008-09-03
HU224711B1 (en) 2006-01-30
EP0973511A1 (en) 2000-01-26
KR20000048567A (ko) 2000-07-25
JP2001500883A (ja) 2001-01-23
GB9619961D0 (en) 1996-11-13
BG64472B1 (bg) 2005-04-30
HUP9903823A3 (en) 2000-07-28
NZ334550A (en) 2000-09-29
TR199900648T2 (xx) 1999-06-21
CA2266378A1 (en) 1998-04-02
BR9711411A (pt) 1999-08-17
CN1231605A (zh) 1999-10-13
AU4774197A (en) 1998-04-17
ES2199354T3 (es) 2004-02-16
PT973511E (pt) 2003-08-29
HUP9903823A2 (hu) 2000-06-28
EP0973511B1 (en) 2003-05-07

Similar Documents

Publication Publication Date Title
CA2266378C (en) Use of sibutramine analogues to lower lipid levels
AU694761B2 (en) Improving glucose tolerance
SK31999A3 (en) Use of sibutramine analogues to prevent the development of diabetes
US6162831A (en) Medical treatment to lower uric acid levels
US6376552B1 (en) Treatment of gallstones
WO2000056318A1 (en) Treatment of neuropathic pain or fibromyalgia
US20050113457A1 (en) Treatment of neuropathic pain or fibromyalgia
US6433020B1 (en) Treatment of cardiovascular disease
MXPA99002633A (en) Use of sibutramine analogues to lower lipid levels
CA2366652A1 (en) Treatment of pulmonary hypertension
CA2367035A1 (en) Treatment of hiatial hernia
CA2367045A1 (en) Treatment of certain cancers associated with weight gain
AU4172900A (en) Weight loss after pregnancy
CA2368416A1 (en) Treatment of gallstones

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20150915